Reflect on the provided data and tweets to anticipate if the closing price of $sny is going to increase or decrease at 2015-06-03. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-05-19,-0.9,0.3,-1.1,1.0,1.0,-0.8,-1.8,-2.3,-2.1,-2.0,-1.9
2015-05-20,-0.6,0.4,-0.8,-0.3,-0.3,-0.1,-1.2,-1.8,-1.7,-1.6,-1.5
2015-05-21,-0.4,0.4,-0.5,1.0,1.0,-0.9,-1.7,-2.4,-2.5,-2.5,-2.4
2015-05-22,0.7,0.7,-0.2,-1.0,-1.0,0.2,-0.6,-1.3,-1.5,-1.5,-1.4
2015-05-26,1.6,1.7,-0.3,-2.8,-2.8,2.6,2.3,1.5,1.3,1.4,1.4
2015-05-27,-1.8,0.5,-1.9,2.8,2.8,-0.3,-0.3,-1.0,-1.4,-1.4,-1.3
2015-05-28,0.2,0.3,-1.0,-0.3,-0.3,-0.1,0.1,-0.6,-1.1,-1.1,-1.1
2015-05-29,1.4,1.5,-1.1,-2.3,-2.3,1.5,2.1,1.8,1.3,1.2,1.2
2015-06-01,0.6,0.8,-0.8,-0.2,-0.2,1.1,2.1,1.9,1.5,1.4,1.3
2015-06-02,0.1,0.7,-0.3,1.0,1.0,0.3,1.0,1.0,0.5,0.3,0.4

2015-05-21: jefferies analyst jeffrey holford target revisions: roche $rog to chf340 from chf315; sanofi $sny €100 from €101; zoetis $zts $60 from $55.
2015-05-22: rt AT_USER that's a pretty broad patient population for evolocumab. bodes well for june us adcom? $amgn $sny $regn 
2015-05-27: rt AT_USER $rtrx sells priority voucher to $sny for $245m over two years.|retrophin bags $245m from sanofi for priority review voucher  $rtrx $sny
2015-05-28: $lly $jnj news: "ec clears boehringer ingelheim's synjardy $lly $sny $jnj $islt"   analyze: 
2015-06-01: esperion therapeutics: etc-1002 is a blockbuster in the making  $regn $sny $espr
Answer:
Reflect on the provided data and tweets to anticipate if the closing price of $sny is going to increase or decrease at 2015-06-03. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-05-19,-0.9,0.3,-1.1,1.0,1.0,-0.8,-1.8,-2.3,-2.1,-2.0,-1.9
2015-05-20,-0.6,0.4,-0.8,-0.3,-0.3,-0.1,-1.2,-1.8,-1.7,-1.6,-1.5
2015-05-21,-0.4,0.4,-0.5,1.0,1.0,-0.9,-1.7,-2.4,-2.5,-2.5,-2.4
2015-05-22,0.7,0.7,-0.2,-1.0,-1.0,0.2,-0.6,-1.3,-1.5,-1.5,-1.4
2015-05-26,1.6,1.7,-0.3,-2.8,-2.8,2.6,2.3,1.5,1.3,1.4,1.4
2015-05-27,-1.8,0.5,-1.9,2.8,2.8,-0.3,-0.3,-1.0,-1.4,-1.4,-1.3
2015-05-28,0.2,0.3,-1.0,-0.3,-0.3,-0.1,0.1,-0.6,-1.1,-1.1,-1.1
2015-05-29,1.4,1.5,-1.1,-2.3,-2.3,1.5,2.1,1.8,1.3,1.2,1.2
2015-06-01,0.6,0.8,-0.8,-0.2,-0.2,1.1,2.1,1.9,1.5,1.4,1.3
2015-06-02,0.1,0.7,-0.3,1.0,1.0,0.3,1.0,1.0,0.5,0.3,0.4

2015-05-21: jefferies analyst jeffrey holford target revisions: roche $rog to chf340 from chf315; sanofi $sny €100 from €101; zoetis $zts $60 from $55.
2015-05-22: rt AT_USER that's a pretty broad patient population for evolocumab. bodes well for june us adcom? $amgn $sny $regn 
2015-05-27: rt AT_USER $rtrx sells priority voucher to $sny for $245m over two years.|retrophin bags $245m from sanofi for priority review voucher  $rtrx $sny
2015-05-28: $lly $jnj news: "ec clears boehringer ingelheim's synjardy $lly $sny $jnj $islt"   analyze: 
2015-06-01: esperion therapeutics: etc-1002 is a blockbuster in the making  $regn $sny $espr
Answer:+Rise